GBCHealth News and Opportunities | June 2012

Read the latest news, updates and information on the Private Sector Delegation (PSD), the Global Fund to Fight AIDS, Tuberculosis and Malaria, and its Board.

This edition of the Global Fund PSD Newsletter contains

A Private Sector Guide to the Global Fund’s New Funding Model

In 2013, The Global Fund to Fight AIDS, Tuberculosis and Malaria launched a new funding model (NFM), aiming to ensure that Global Fund grants reach areas of greatest need and achieve the highest possible impact against the three diseases. The process countries undertake to develop programs and access funding was re-designed to be more inclusive, predictable and flexible than the previous model. With the NFM’s new ways of working come new opportunities and challenges for Global Fund partners, including the private sector.

But what exactly does the new model mean for the private sector? Have opportunities for companies to partner with the Global Fund or to contribute to the fight against AIDS, TB and malaria changed? Read the Private Sector Guide to the Global Fund NFM to find out.

IAC 2014 Highlights Private Sector Action on AIDS

July 20-25, 2014 | Melbourne, Australia

The 20th International AIDS Conference (IAC), themed Stepping up the Pace, presented new scientific knowledge and opportunities for structured dialogue on the major issues facing the global response to HIV. High-level speakers included former U.S. President Bill Clinton, UNAIDS Executive Director Michel Sidibé, and activist and artist, Sir Bob Geldof.

Private sector initiatives and Global Fund corporate partners, including Chevron, BHP Billiton, Oil Search, Abt Associates and others, were highlighted in a number of sessions. Read more about IAC and private sector representation here.

Newly-Appointed Private Sector Representative Attends Global Fund Committee Meetings

In June, newly-appointed members of the Global Fund Board’s three standing committees met in Geneva. The meetings provided the first opportunity for Board constituencies to discuss important information from the first three months of full implementation under the Global Fund’s new approach to funding, following the 31st Board Meeting in March 2014. Committees also discussed progress in developing baselines and indicators for the Fund’s performance framework, early plans for a comprehensive strategic review in 2015, and other topics.

The private sector is represented on the Finance and Operational Performance Committee (FOPC) by Advisory Group member Nazzareno (Naz) Todini (Chief of Party, Health Finance and Governance Project, Abt Associates), who was appointed to the role in May 2014. Mr. Todini brings strong experience in international public health and financial management to the Committee, and will serve a two-year term, through the end of the 36th Board Meeting in 2016.

“Abt Associates has been a dedicated and valuable member of the PSD for many years, and we are excited to have Naz representing the private sector on this important Committee, given his considerable expertise and experience,” said Paul Schaper, PSD Board Member. “The private sector brings particular skills to the FOPC and a strong voice to help shape the Committee’s work. Over the coming two years, the FOPC will be addressing several critical issues, including oversight of the Global Fund’s new financial management policy, the operation of the new funding model, improved risk management, and the Fund’s performance evaluation framework.”

Opportunities for Corporate Sector Engagement in Malaria Control in the Asia-Pacific

September 29, 2014 | Yangon, Myanmar

Malaria elimination and control in Asia-Pacific is a crucial public health issue. Emerging parasite resistance to drugs and insecticides threaten to compound an already challenging epidemic. As the region readies for an economic boom in countries such as Myanmar and Viet Nam, there is a real threat of losing the gains made against malaria and significant losses in human capital and resources unless action is taken now. Recognizing that corporate participation is essential to malaria control and elimination efforts, regional and global partners will convene a private sector-focused forum in Yangon, Myanmar in late September.

The forum will be hosted by Asia Pacific Leaders Malaria Alliance (APLMA), Roll Back Malaria Partnership and GBCHealth, in partnership with The Global Fund to Fight AIDS, Tuberculosis and Malaria, Malaria No More and Myanmar Health and Development Consortium, and with the support of Sanofi. Bringing together local, regional, and multi-national private sector companies, government representatives, Chambers of Commerce, bi-lateral and multi-lateral development partners, the event will aim to catalyze private sector action to address malaria challenges including resistance, stimulate cross-sector collaboration for workplace and community initiatives and expand the reach and impact of region-wide malaria efforts such as WHO’s Emergency Response to Artemisinin Resistance and the Global Fund’s Regional Artemisinin Initiative in the Mekong Region.

For more information on the event, please contact Fareeda Ehtesham at

Novartis to Host 4th Annual PSD Retreat

The 2014 Annual PSD Retreat will focus on setting strategic priorities for the coming year and discussing PSD positions on key Global Fund issues. The group will evaluate effectiveness and results of the internal taskforce structure put in place last year, discuss priorities for strengthening private sector partnership with the Fund, including under the new approach to funding, and prepare for the upcoming Board Retreat and 32nd Board Meeting in Montreux, Switzerland scheduled for mid-November. The meetings are open to PSD Advisory Group and Affiliate members only. Contact for more information.

The Global Fund’s Innovation Coalition: Turning Challenges into Opportunities

The Global Fund to Fight AIDS, Tuberculosis and Malaria recently launched the Innovation Coalition, a global, multi-sector partnership platform designed to draw on the innovations, creative energy and solution-oriented approaches of private sector companies, academia and civil society to help solve recurring challenges encountered by Global Fund grant recipients. The Innovation Coalition will identify high-impact opportunities to strengthen grant performance, determine how private sector collaboration can unlock effective solutions, and pilot these innovative approaches together with multi-sector partners.

Leading private sector companies from across industries, including consumer goods, healthcare and pharmaceutical products, transportation, logistics, insurance, banking, and information and communication technology, have already joined the Innovation Coalition. Read more about the Global Fund’s Innovation Coalition and how your company can get involved.

Global Fund Presents on Private Sector Opportunities at Malaria Forum in Nigeria

Global Fund representatives highlighted opportunities in the new funding model for increased private sector impact on malaria control at a high-level Malaria Forum in Abuja, Nigeria last month. Hosted by GBCHealth’s Corporate Alliance on Malaria in Africa (CAMA), in partnership with the Nigeria Federal Ministry of Health, National Malaria Elimination Program, Access Bank, and Friends Africa, the Forum explored the integration of malaria control with maternal and child health programming. The Global Fund presented private sector opportunities specific to Nigeria and underscored the business case for action. Forum attendees included 128 leaders from government, private sector, multilateral agencies, NGOs and academia.

CAMA brings the collective force and voice of the private sector to improve the impact of malaria control and elimination efforts in Africa by promoting multi-company and multi-sector partnerships, exchanging knowledge and best practices, and building country-level capacity for effective malaria control and elimination. GBCHealth serves as the Secretariat for CAMA. Learn more here.

Roll Back Malaria Private Sector Constituency Newsletter

The Private Sector Constituency (PSC) to the Roll Back Malaria Partnership (RBM) published its bi-annual Newsletter in June 2014. The Newsletter provides a summary of key decisions taken at the RBM’s 26th Board meeting (Geneva, May 2014). The PSC elected new leadership: Jon Pender (GlaxoSmithKline) and Lisa Goldman-Van Nostrand (Sumitomo Chemical) as Board Members, and Nancy Nachbar (Abt Associates) and Sherwin Charles (Nando’s) as Alternates. The Newsletter also summarizes the process to develop the second iteration of the Global Malaria Action Plan and offers private sector perspectives on drug and insecticide resistance. Read the Newsletter here.

Regional Proposals Indicate Strong Demand for Cross-Border Initiatives

In May, the Global Fund received 43 expressions of interest (EOIs) from regional applicants for proposals totaling $689 million, far exceeding the $120 million envelope set for the 2014 window. Programs will be screened for eligibility and technical soundness by the independent Technical Review Panel and the Secretariat’s Grant Approval Committee, after which successful proposals will be allocated an indicative funding amount and invited to submit fully-developed concept notes.

The May deadline was the first milestone in the new process for regional applications approved by the Global Fund Board in March of this year. Implemented across multiple countries, regional programs use interventions that can have a greater impact through cross-border and multi-country collaboration. There will be a second opportunity for regional EOIs to be submitted in April 2015, when an additional $80 million will be available.

The majority of EOIs were from sub-Saharan Africa, with 20 applications for a total of $431 million. Over two-thirds of the EOIs focused on HIV/AIDS – 29 submissions amounting to $347 million. TB programs were the second-most numerous, with 8 submissions amounting to $222 million, while submissions for malaria totaled 5 and $84 million. Private sector organizations were included as key partners in several submitted EOIs, including a proposal to implement sustainable, scalable TB care through the private sector in Asia, and a proposal to address the prevalence of TB among mining communities in Southern Africa.

Nancy Wildfeir-Field Appointed New GBCHealth President

GBCHealth announced the appointment of Nancy Wildfeir-Field as its new President, effective June 2, 2014. Nancy brings to GBCHealth extensive international experience in both global health and the private sector, having most recently served as Director, Global Partnerships for BSR (Business for Social Responsibility). Nancy also held positions with USAID in the Caribbean and Eastern Europe, The Prince of Wales International Business Leaders Forum (IBLF) and Burson-Marsteller, and worked as a consultant to the UK Ministry of Health. The appointment follows the departure of Michael Schreiber, Executive Director.

“Nancy’s rich and diverse experience will allow her to drive GBCHealth forward as the world’s foremost expert on business engagement in global health,” said Ray Chambers, Co-Chair of the GBCHealth Board. “With fewer than 500 days remaining to achieve the MDGs and a need to protect hard-won health progress beyond 2015, Nancy’s leadership in harnessing business resources for global health goals will be vitally important.”

Wildfeir-Field underlined the importance of the PSD and the Global Fund, stating, “Private sector engagement is increasingly important in affecting solutions to some of the world’s most complex issues. The PSD has an impressive track record on issues across the Global Fund’s portfolio. The work of the PSD and the Global Fund remains central to GBCHealth’s strategic priorities, as we work with companies to address key health issues and to maximize results and impact.”

Johnson & Johnson’s Janssen Global Public Health Joins PSD Advisory Group

Johnson & Johnson became the newest company to join the PSD Advisory Group in April 2014. Johnson & Johnson will be represented on the PSD by its subsidiary, Janssen Global Public Health, a company dedicated to improving access to and affordability of drugs, identifying and developing vaccines, diagnostics, and medicines to address neglected diseases and unmet medical needs. Janssen recently introduced a new treatment option for MDR-TB. Through public-private partnerships in R&D, differentiated pricing and collaborations around responsible use and distribution, Janssen is working to ensure the product is accessible in countries where it is approved for use.

“We welcome Johnson & Johnson as the newest member and look forward to their contributions to the PSD. Our PSD members share a common goal of ensuring high quality health access to all people being supported by the Global Fund, and it is a pleasure to have Johnson & Johnson join this collective dialogue,” said Renuka Gadde, Alternate Board Member for the PSD.

Jami Taylor, Senior Director for Global Access Policy at Janssen Global Public Health, will represent Johnson & Johnson on the Advisory Group and in the PSD’s Health Systems Strengthening taskforce.


ELI LILLY: Eliminating Mother-to-Child Transmission of HIV in Nigeria

Most TB drugs currently approved for treatment are 50+ years old and are required to be taken over a 6-month period to be effective. Compliance with such a long treatment regimen is a challenge, limiting drugs’ effectiveness and contributing to the rise in MDR-TB. As part of its MDR-TB Partnership, Eli Lilly and Company formed innovative partnerships with the Infectious Disease Research Institute (IDRI) and the Bill and Melinda Gates Foundation to discover new and more effective TB drugs. These partnerships draw on the expertise of private sector companies like Lilly and seek multi-sector solutions to accelerate progress in the fight against TB. Read more about Lilly’s innovative partnerships here.

Meet the PSD

Erika Satterwhite, Mylan Rene Cazetien, Sanofi

Erika Satterwhite,
Manager, Global Policy, Mylan

René Cazetien,
Associate Vice President Operations, Access to Medicines, Sanofi

How did Mylan become involved with the Global Fund?

Mylan’s decision to join the PSD Advisory Group is rooted in the company’s desire to provide the often-missing generic manufacturer’s perspective in shaping good public policy around the Global Fund’s efforts to combat HIV/AIDS, TB, and malaria. Mylan is the world’s largest manufacturer of antiretroviral drugs to treat HIV/AIDS, but is committed to going beyond the traditional role of a product supplier. Through the PSD, Mylan is able to engage in passionate global leadership to encourage sustainability and efficiency in Global Fund operations. In addition to joining the PSD, Mylan also supports the Global Fund through advocacy activity in Washington, D.C. and work with implementing partners in grant recipient countries.

How did Sanofi become involved with the Global Fund?

Sanofi has been engaged on improving access to medicines since 2002 with a strong focus on treatments for malaria. We began working with the Roll Back Malaria Partnership (RBM) and the Stop TB Partnership and also participated on the RBM Board. As these two organizations work closely with the Global Fund and the Global Fund is the main funder for HIV/AIDS, TB and malaria programs, it was a natural extension of our work to partner with the Global Fund. Sanofi became involved with the Global Fund in 2005.

Read the full interviews here.


September 8-9

12th Finance and Operational Performance Committee Meeting

Geneva, Switzerland

September 16-23

69th United Nations General Assembly

New York, United States

September 29

Opportunities for Corporate Sector Engagement in Malaria Control in Asia-Pacific: Forum and Reception

Yangon, Myanmar

October 7-9

13th Strategy Investment and Impact Committee Meeting

Geneva, Switzerland

October 8-9

10th Audit and Ethics Committee Meeting

Geneva, Switzerland

October 20-21

4th Annual PSD Retreat

Basel, Switzerland

October 22-23

1st Annual RBM Private Sector Retreat

London, United Kingdom

November 16-18

Global Fund Board Retreat

Montreux, Switzerland

November 18

PSD Pre-Board Meeting

Montreux, Switzerland

November 19-21

32nd Global Fund Board Meeting

Montreux, Switzerland



Partnership with Nigerian Ministry of Health to roll out TB Testing Innovation


New Point-of-Care System for HIV/AIDS Patients


2013 Corporate Responsibility Report Released


First antimalarial treatments produced by Sanofi with semisynthetic artemisinin enter market

More Advisory Group News here.


31 July 2014

Global Fund Welcomes Germany’s Increased Contribution

17 July 2014

Global Fund Results Show Strong Gains

24 June 2014

New Framework on Malaria Drugs to Save $100 Million

19 June 2014

Gender Issues Featured at Regional Meeting

13 June 2014

UNITAID and the Global Fund Announce Formal Collaboration

20 May 2014

WHO and Global Fund Strengthen Partnership

09 May 2014

Global Fund and Munich Re in Risk Management Partnership

22 April 2014

UNICEF and Global Fund Coordinate Efforts to Reach Mothers, Newborns and Children

10 April 2014

Latin America Mobilizes Partnerships in New Funding Model

09 April 2014

Innovative Investment in Indonesia Health Fund

07 April 2014

Partners in Eastern and Southern Africa Look at Investment Framework

02 April 2014

Global Fund Taps Pharmaceutical Expertise in China

Private Sector Delegation Companies and Represenatives

Board Member: Paul Schaper, Executive Director, Global Public Policy, Merck & Co./MSD

Alternate Board Member: Renuka Gadde, Vice President, Global Health, BD

Advisory Group Members


Matthew Hamada, Senior Product Manager, Virology

Claudia Carravetta, Director, Government Affairs


Naz Todini, Chief of Party, Health Finance and Governance Project


Omobolanle Babatunde, Head, Corporate Communications & Sustainability


Dr. Brian Brink, Chief Medical Officer


Dr. Gerhard Hesse, Head of Global Partnering/Vector Control

BD (Becton, Dickinson and Company)

Renuka Gadde, Vice President, Global Health


Amy Israel, Program Manager, Global Health Programs & Access

Dr. Evan Lee, Vice President, Global Health Programs & Access


Graeme Robertson, Director, Access Operations & Emerging Markets

Polly Fields, Director, Government Affairs


Jami Taylor, Senior Director, Global Access Policy


Paul Schaper, Executive Director, Global Public Policy


Erika Satterwhite, Manager, Global PolicyScott Evertz, Consultant


Rebecca Stevens, Director of Public Affairs, Novartis Malaria Initiative


Luisa Engel, Senior Manager of ONE/(RED) Special Projects


René Cazetien, Associate Vice President of Operations, Access to Medicines


Heloisa Jardim, Global Health Corporate Analyst, Health & Safety Department

Patricia Pena, Corporate Health Manager

Current Affiliate Members


Anastasia Thatcher, Global Health Lead


GBCHealth is the Focal Point for the Private Sector Delegation to the Global Fund, working with the committed companies of the Advisory Group to steer Global Fund priorities and policies, while also ensuring that the Global Fund actively engages the business sector.

For more information on how your company or private sector organization can get involved, please contact PSD Focal Point, Whitney White at Learn more about the Private Sector Delegation.